Rate My Professor Longqin Hu

Hu's research centers on synthetic medicinal chemistry and bioorganic chemistry, encompassing the design of anticancer prodrugs for site-specific activation in tumor tissues, particularly for prostate cancer; small molecule inhibitors of protein-protein interactions including Keap1-Nrf2 and PD-1/PD-L1; and crystallization inhibitors for kidney stone diseases such as cystinuria, hyperoxaluria, and hyperuricosuria. Key developments include L-cystine diamides LH707 and LH708, orally bioavailable inhibitors of L-cystine crystallization that demonstrated efficacy in a cystinuria mouse model and were licensed to PharmaKrysto for further development. Hu serves as Editor-in-Chief of Medicinal Chemistry Research since 2020, following his tenure as Associate Editor-in-Chief of Acta Pharmaceutica Sinica B from 2011 to 2019, and is a member of the Long Range Planning Committee of the American Chemical Society Division of Medicinal Chemistry. He co-edited the book Drug Delivery: Principles and Applications, Second Edition (John Wiley & Sons, 2016), contributed chapters on prodrug design, and holds multiple patents, such as US 11,628,221 B2 (2023) on peptide-linked prodrugs activated by prostate-specific antigen and US 11,420,949 B2 (2022) on cystine diamide analogs for cystinuria. Recent publications include '8-L-Cystinyl bis(1,8-diazaspiro[4.5]decane) as an orally bioavailable L-cystine crystallization inhibitor for cystinuria' (ACS Med. Chem. Lett., 2024) and 'Structure-activity relationships and pharmacokinetic evaluation of L-cystine diamides as L-cystine crystallization inhibitors for cystinuria' (Med. Chem. Res., 2024).